Status:
COMPLETED
Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Psoriasis
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis treated for 28 days.
Eligibility Criteria
Inclusion
- Diagnosed with chronic plaque psoriasis for at least 6 months
- Prior systemic therapy
Exclusion
- Current or prior history of illness precluding use of immunomodulatory therapy.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00205465
Start Date
December 1 2004
End Date
September 1 2005
Last Update
December 5 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.